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Abstract
Background: Lung cancer is a multistage process with poor prognosis and high morbidity. Importantly, the genetics of
dysplasia, a facultative cancer, at the edge of malignant transformation is unknown.
Methodology/Principal Findings: We employed laser microdissection to harvest c-Raf1- induced dysplastic as opposed to
transgenic but otherwise morphologically unaltered epithelium and compared findings to non-transgenic lung. We then
employed microarrays to search genome wide for gene regulatory networks. A total of 120 and 287 genes were significantly
regulated, respectively. Dysplasia was exclusive associated with up-regulation of genes coding for cell growth and
proliferation, cell-to-cell signalling and interaction, lipid metabolism, development, and cancer. Likewise, when dysplasia
was compared with non-transgenic cells up-regulation of cancer associated genes, tight junction proteins, xenobiotic
defence and developmental regulators was observed. Further, in a comparison of the data sets of dysplasia vs transgenic
and dysplasia vs non-transgenic 114 genes were regulated in common. We additionally confirmed regulation of some genes
by immunohistochemistry and therefore demonstrate good concordance between gene regulation and coded protein.
Conclusion: Our study identified transcriptional networks at successive stages of tumor-development, i.e. from histological
unaltered but transgenic lungs to nuclear atypia. Our SP-C/c-raf transgenic mouse model revealed interesting and novel
candidate genes and pathways that provide clues on the mechanism forcing respiratory epithelium into dysplasia and
subsequently cancer, some of which might also be useful in the molecular imaging and flagging of early stages of disease.
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Introduction
The lung cancer epidemic was the subject of a recent editorial
[1]. Indeed, in Europe alone more than 340 000 death per annum
are attributable to this cancer, but this disease is by large
preventable. There is concluding evidence for tobacco smoke to be
the primary cause of lung cancer and more than 4,800 compounds
have been identified in the particulate and gas phases of cigarette
smoke. Major lung carcinogens in smoke include some of the
polycyclic aromatic hydrocarbons, such as benzo[a]pyrene, as well
as tobacco-specific N-nitrosamines. Although a lot of evidence
supports the relationship between cigarette smoking and lung
cancer, the molecular events associated with early stages of disease
remain somewhat elusive. A diverse range of genetic abnormalities
are seen in different stages of lung cancer, some of which may be
employed as markers of disease progression; others may have a
direct role in lung cancer etiology in the context of gene-
environment interactions. Characterisation of the cancer genome
in lung adenocarcinoma was the subject of a recent study and
several reviews [2,3,4].
Specifically, eighty percent of the lung cancers are classified as
non-small cell lung cancer (NSCLC) whereas the remains 20% are
small cell lung cancer (SCLC). Survival of patients diagnosed with
non-small-cell lung cancer (NSCLC) is poor; over the last decades
the 5-year survival rate remained less than 15%. Survival of lung
cancer is, however, strongly associated with the stage of disease at
the time of diagnosis. Indeed, 5- year survival rates range from 5%
for patients with stage IV lesions to 70% at stage I [5]. Such
encouraging outlooks have lead to renewed interest in the search
and validation of biomarkers of disease to allow monitoring of
individuals at risk for developing lung cancer [6]. Most frequently,
diagnosis of lung cancer is at a late stage of disease with its
classification being based on morphological appearance and
immunohistological methods [7]. An identification of patients at
risk for developing cancer at early stages of disease would have a
big impact on overall survival. Notably, there has been significant
progress in an understanding of the molecular pathogenesis of lung
cancer, which includes an identification of genetic and epigenetic
events in cancer subgroups [8]. The molecular perturbations
associated with early stages of lung cancer are, however, unknown
as are the gene regulatory networks forcing dysplastic cells into
malignant transformation.
Previous studies had defined atypical adenomatous hyperplasia
(AAH) as a preinvasive lesion that progresses from low to high
grade dysplasia to invasive adenocarcinoma [9]. Strikingly, the
genetic events associated with dysplasia and its progression into
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grade dysplasia the architectural and cytological changes of the cell
are minimal, while with high grade dysplasia gross cytological
irregularities become obvious with larger, columnar cells,
cytoplasmic pleomorphism, large hyperchromatic nuclei, uneven
chromatin structure and higher mitotic rates. Although these
morphological changes are well recognized, the underlying
molecular alterations are at best poorly understood. Through
the use of refined experimental models new insight into the
molecular events associated with dysplasia and its progression into
cancers can be obtained.
Here we report findings with a transgenic mouse model, where
targeted overexpression of c-RAF to respiratory epithelium
resulted in lung cancer development [10]. A serum and lung
adenocarcinoma proteome map of the SP-C/c-raf transgenic line
was recently published by us [11,12]. We also published the
molecular organisation of the c-raf promoter [13]. Specifically, the
raf family (a-raf, b-raf and c-raf) of proteins code for serine/
threonine kinases, originally isolated as a viral oncogene
contributing to cellular transformation and are one of the best
characterized Ras effectors to activate the mitogen-activated
protein kinase (MAPK) signaling pathway [14]. RAF directly
phosphorylates and activates MEK via two conserved serine
residues in the kinase activation loop of MEK [15]. Activated
MEK then directly phosphorylates a conserved tyrosine and
threonine residue in the kinase activation loop of ERK [16]. The
MAPK pathway is deregulated in many human malignancies
through aberrant signaling upstream of the protein and by
activating mutations of the protein itself, both of which induce a
proliferative advantage. Indeed, mutations of the K-ras gene have
been identified in up to 30% of lung adenocarcinomas and have
been considered as a poor prognostic factor [17] underscoring the
important role of this pathway in human lung cancer.
As of today, the genetic events associated with dysplasia are
basically unknown. We therefore aimed for an identification of
preneoplastic changes in a c-raf-1 lung cancer disease model. In
our study, we used predominately 5 month old mice to gain
information at an early stage of tumor development where isolated
foci of transformed cells in distinct areas of the lung are visible. By
use of laser microdissection pressure catapulting (LMPC) dysplas-
tic cells in well defined lesions [18] could be isolated. Dysplastic
lesions were than compared with transgenic but otherwise normal
cells or tumor cells. We applied gene expression profiling to
determine differentially expressed genes as to identify the gene
regulatory networks associated with dysplasia. Overall, our study
revealed interesting and novel genes and pathways that may
contribute to the early stages of lung cancer development many of
which are worthy for their exploration as candidate biomarkers
and for molecular imaging of early stages of disease.
Results
Histological changes
Animals at the age of 5 month displayed morphological changes
typical for dysplasia. Note, Figure 1 depicts lung tissue from
transgenic mice where columnar epithelium, typical for bronchi-
oles with vertically oriented nucleus is replaced by cells displaying
horizontal orientation. Cytologically nuclei of different size and
unevenly arranged chromatin are observed. Nuclei are hyper-
chromatic, often with prominent nucleoli. The shapes of the nuclei
are irregular and the ratio of nucleus to cytosol area is grossly
changed.
SAM (Significance Analysis of Microarrays)
120 genes were significantly regulated when transgenic but
otherwise unaltered cells were compared with dysplastic cells
(Supplementary Table S1). Strikingly, dysplasia is exclusively
associated with induction of transcript expression. In contrast,
when transcript expression in dysplasia was compared with non-
transgenic lung tissue 234 up-regulated and 53 down-regulated
genes could be determined (Supplementary Table S2). For this
comparison, we requested at least 2-fold differentially expressed
genes at an estimated false discovery rate of #0.001 (Table 1).
Notably, transgenicity alone was associated with 16 up-regulated
and 2 down-regulated genes (Supplementary Table S3). We
searched for differentially expressed genes by comparing the data
sets of dysplasia vs transgenic and dysplasia vs non-transgenic. In
such a comparison 114 genes were regulated in common (Figure 2).
Notably, we used this stringent cut-off because we desired a
smaller number of genes with very low false positive rates on which
to focus our attention. With an estimated false discovery rate of 0.1
we obtained in dysplasia 2352 significantly regulated genes (867
Figure 1. Histological analyses of lung tissue from 5-month-old transgenic mice. Histological analyses of lung tissue from mice transgenic
for lung-targeted expression of the cRaf-1 protein. Lung tissue from a 5-month-old SP-C-c-Raf mouse were sectioned at 10 mm, fixed in methanol/
acetig acid and stained with H&E. We detected single dysplastic foci, whereas in 10-month-old SP-C-c-Raf mice were multiple foci. A: Overview
presentation (magnification: 650), B: dysplastic foci (magnification: 6200).
doi:10.1371/journal.pone.0005637.g001
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but unaltered cells and 3311 genes (1279 up-regulated and 2032
down-regulated) in dysplasia versus non-transgenic cells. Compar-
ison of these data sets resulted in 2207 genes regulated in common
in dysplasia (data not shown).
Principal component analysis (PCA) and hierarchical gene
cluster analysis (HCA)
The expression levels were analyzed by the GCOS and
ArrayTrack software. We initially examined the data in a 34,000
genes 615 sample matrix. The PCA classified the data into 3
major groups, namely non-transgenic, transgenic and dysplasia
(Figure 3).
We also applied hierarchical gene cluster analyses after SAM
analysis. The closest pair of expression values of 2909 differentially
expressed genes was grouped together. Consequently, the data are
organized in a phylogenetic tree in which the branch lengths
represent the degree of similarity between the expression values. A
clear segregation of the analyzed groups (dysplasia, transgenic but
unchanged lung tissue and non-transgenic lung tissue) was
obtained (Figure 4). The PCA and HCA grouped data according
to their biological state. Correspondingly, gene expression data of
transgenic SP-C/c-raf lung were well separated from non-
transgenic and dysplastic cells, suggesting a large difference
between these groups.
Figure 2. Venn diagram for significantly regulated genes. Venn diagram for significantly up-regulated genes. Comparison of dysplasia and
transgenic unaltered lung tissue with non-transgenic samples. 114 genes were found in dysplasia, respectively, which were at least 2-fold
differentially expressed (FDR=0.001).
doi:10.1371/journal.pone.0005637.g002
Table 1. Overview of significant differentially expressed
Genes (FDR=0.001, FC #2$).
non-transgenic transgenic dysplasia
non-transgenic 0 18 287
transgenic 18 0 120
dysplasia 287 120 0
doi:10.1371/journal.pone.0005637.t001
Figure 3. Principal component analysis for gene expression
profiles of transformed cells. Principal component analysis of
transformed cells from transgenic SP-C/c-raf mouse model in compar-
ison to unaltered lung tissue of transgenic and non-transgenic mice
were conducted using the autoscaled method within ArrayTrack.
orange; dysplasia; blue, transgenic non-tumor sample; green, non-
transgenic samples.
doi:10.1371/journal.pone.0005637.g003
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We employed the Ingenuity Pathways Analysis software and
over 70% of regulated genes were mapped to different networks in
the IPA database. These networks describe functional relationships
among gene products based on findings presented in peer-
reviewed biological pathways. Taken collectively, 12 and 16
networks could be defined for the comparison dysplasia vs
transgenic and dysplasia vs non-transgenic cells. Based on pathway
analysis the top 2 and top 3 networks reached a score of 25 or
higher and contained 15 or more genes in the comparison
dysplasia vs transgenic (Figure 5) and dysplasia vs non-transgenic
cells (Figure 6), respectively. This demonstrates the extensive
relationship and interaction between the significantly regulated
genes in dysplasia. These networks were associated with the
following pathways: cellular growth and proliferation, cell-to-cell
signalling and interaction, cancer, lipid metabolism, development,
cellular movement amongst others (Supplementary Figure S1). In
the following, we describe prominent examples. Cancer cells may
produce their own growth factors to stimulate proliferation in
neighbouring or parental cells (paracrine vs autocrine loops). We
Figure 4. Result of the hierarchical cluster analysis. The normalized data were used for the Ward’s Minimum Variance linkage clustering
algorithm. A total of 2909 differentially expressed genes (mean channel intensity .100, FDR: 0.1, Bad Flags: 5) were used in the cluster dendogram to
obtain a clear segregation of the analyzed groups (dysplasia, transgenic and non-transgenic). The similarity of gene expression profiles among
experimental samples is summarized in a dendogram above the cluster, in which the pattern and the length of the branches reflect the relatedness of
the samples. Groups (dysplasia, transgenic and non-transgenic) are presented by columns, and genes in rows. Expression values were colour coded
with a red green scale. Green, transcript levels below the median; black, equal to the median and red, greater than median.
doi:10.1371/journal.pone.0005637.g004
Genetics of Dysplasia in Lung
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5637thus searched for genes involved in cellular growth and
proliferation and found in the case of dyspalsia 18 genes to be
up-regulated ranging between 3.6 to 23.5-fold as compared to
transgenic but morphologically unaltered lung tissue. Likewise 36
genes were up-regulated between 4.7 to 482.2-fold when
compared to non-transgenic lung tissue. In particular, the Areg
(amphiregulin) and Ereg (epiregulin) ligands, both members of the
EGF-pathway, were highly significantly over expressed. These
molecules play pivotal roles in an activation of the EGF receptor
tyrosine kinase to foster proliferation and motility. Overexpres-
sions of these EGF-ligands are observed in a wide variety of
human cancers, including breast, prostate and lung cancer.
Cell-to-cell interactions are also important for the regulation of
cell proliferation and differentiation. Indeed, expression of cell
adhesion molecules is programmed during development to provide
positional and migratory information for cells. Disruption of these
adhesion events leads to increased cell motility and potential
invasiveness trough remodelling of the extra cellular matrix.
We found genes coding for tight junction proteins to be
regulated. Identification of the molecular components of the tight
junction evidenced that, in addition to their structural functions,
these proteins play central roles in regulating cellular proliferation
and differentiation. Under normal conditions, tight junctions act to
segregate a growth factor within the apical membrane compart-
ment away from its receptor in the basolateral membrane
compartment, thereby precluding receptor activation [19]. The
disruption of tight junctions in adjacent healthy cells permits the
growth factor to bind and activate its receptor, thereby inducing
cellular proliferation and migration. In dysplasia the claudins
Cldn2, Cldn4 and Cldn8 were significantly up-regulated, their
expression ranged from 4.6–13.31-fold and 4.9–122.38-fold, when
transgenic but healthy and non-transgenic lung tissue were
compared, respectively. Overexpression of these tight junction
proteins suggest remodelling of tight junctions.
Next to claudins, we observed up-regulation of gap junction
proteins in dysplasia by 11 and 9-fold as well (Gja3, gap junction
Figure 5. Ingenuity networks: dysplasia versus transgenic mice. Ingenuity networks generated by mapping the focus genes that were
differentially expressed between dysplasia and transgenic unaltered lung tissue. Each network is graphically displayed with genes/gene products as
nodes (different shapes represent the functional classes of the gene products) and the biological relationships between the nodes as edges (lines).
The length of an edge reflects the evidence in the literature supporting that node-to-node relationship. The intensity of the node color indicates the
degree of up- (red) or down-regulation (green) of the respective gene. A solid line without arrow indicates protein-protein interaction. Arrows
indicate the direction of action (either with or without binding) of one gene to another. IPA networks were generated as follows: Upon uploading of
genes and corresponding fold-change expression values (done separately for dysplasia vs transgenic and dysplasia vs non-transgenic differentially
expressed genes), each gene identifier was mapped to its corresponding gene object in the IPA Knowledge Base (part of the IPA algorithm). Fold-
change expression values were used to signed genes whose expression was differentially regulated; these ‘‘focus genes’’ were overlaid onto a global
molecular network contained in the IPA Knowledge Base. Networks of these focus genes were then algorithmically generated based on their
connectivity and scored according to the number of focus genes within the network as well as according to the strength of their associations.
doi:10.1371/journal.pone.0005637.g005
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in gap junctional intercellular communication results in the
inability of cells to receive apoptotic, growth suppressing or
differentiation signals from their neighbours. Specifically, connex-
ins, a family of 20 trans-membrane proteins in humans, comprise
the main subunits of gap junctions; – these specialised clusters of
intercellular channels allow adjacent cells to directly share ions and
hydrophilic molecules of up to ,1 KDa in size. Gap junctional
intercellular communication is thought to control tissue homeo-
stasis and to coordinate cellular processes such as proliferation,
migration and differentiation. Disruption of gap junctional
intercellular communication or mutations in connexins is
associated with several human diseases. Notably, gap junction
expression is often up-regulated in hyperplastic tissues.
Furthermore, lipid metabolism is altered in cancer, including
loss of body fat early in tumor growth, induction of hyperlipidemia
and changes in a variety of serum lipid and lipoprotein fractions.
Thus, cancer patients were found to have higher rates of fat
oxidation when compared with healthy individuals with equal
weight loss [20,21]. We examined genes involved in lipid
metabolism and found up to 13 genes in dysplasia to be up-
regulated ranging from 3.6–28.1-fold and 4.4–148.4-fold when
unaltered transgenic and non-transgenic lung tissue was compared
with dysplastic cells. In particular Apoa1 (apolipoproteinA-1) the
major apoprotein of High Density Lipoprotein (HDL) was
significantly over expressed. Apoa1 is a cofactor for Lcat
(lecithin-cholesterin-acetyltransferase), which is responsible for
the formation of most cholesterol esters in plasma. Apoa1 also
promotes efflux of cholesterol, phospholipids, sphingomyelin,
sterol and phosphatidylcholin from cells and is involved in
transport of cholesterol ester. Recently, it has been observed that
the HDL complex is capable of suppressing lymphocyte function,
particularly in the host resistance to tumors [22].
In this regard we also found changes in the expression of cell
surface glycolipids in dysplastic cells as compared to unaltered
transgenic or to non-transgenic lung tissue. For example, Sult2b1
(sulfotransferase family 2b, member 1) was significantly over
expressed. This enzyme catalyzes the sulphate conjugation of
pregnenolone and cholesterol. Moreover, St8sia6 (St8 alpha-n-
acetyl-neuraminide alpha-2,8-sialyltransferase 6), an enzyme
which synthesize sialylglycoconjugates of glycolipids was signifi-
cantly up-regulated, as well. These changes may result in new
surface antigens and glycolipids in addition to altered cell-cell and
cell-extracellular matrix communication followed by decreased
adhesiveness and invasiveness through normal tissue barriers.
Further evidence for changes in glycosylation patterns during
transformation of normal cells into malignant ones stems form the
up-regulation of B4galt6 (UDP-GAL:Beta-GlcNAc Beta-1,4-Ga-
Figure 6. Ingenuity networks: dysplasia versus non-transgenic mice. Ingenuity networks generated by mapping the focus genes that were
differentially expressed between dysplasia and non-transgenic unaltered lung tissue (descriptions see Fig. 6).
doi:10.1371/journal.pone.0005637.g006
Genetics of Dysplasia in Lung
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5637lactosyltransferase, polypeptide 6), Fut2 (Fucosyltransferase 2),
Gpc6 (Glypican6) and Orm1 (orosomucoid1) as observed in
dysplastic cells. The synthesis of new carbohydrate chains in
dysplastic cells are due to activation of glycosyltransferase such as
B4galt6, which catalyzes the reaction UDP-galactose and N-
acetylglucosamine for the production of galactose beta-1,4-N-
acetylglucosamine. Strikingly, these carbohydrates are absent or
have low activity in normal cells. Moreover, the secretor enzyme
Fut2, an a-1,2-fucosyltransferase, is responsible for the transfer of
fucose in an a-1,2 linkage to form the terminal H type 1 structure.
The extra fucosylations that appear on membrane glycoproteins
and glycolipids are associated with several pathological processes,
such as tumor metastasis, inflammation and bacterial adhesion.
As the expression of glycoproteins is increased in many cancers, it
was of no surprise that Orm1 was 11.1-fold overexpressed in
dysplastic cells. Orosomucoid 1 belongs to a group of highly
glycosylated glycoproteins and appears to function in modulating
the activity of the immune system. Furthermore, we found glypican
6 to be induced (9.9-fold). Notably, this protein belongs to a family
of glycosylphosphatidylinositol-anchored heparin sulphate proteo-
glycans. It is known that proteoglycans are high-molecular-weight
glycoproteins and interact via their multiple binding domains with
many other structural macromolecules. They are bound together
with extracellular matrix components and act as cell adhesion
factors by promoting organization of actin filaments in the cell
cytoskeleton. Proteoglycans havebeenshown to undergoalterations
during malignant transformation resulting in disrupted interaction
between the extra cellular matrix and the transformed cells to
simplify the invasion into the surrounding tissue.
We further investigated genes involved in developmental
processes and found 8 genes to be 3.6–15.4-fold up-regulated in
dysplasia as compared to transgenic lung tissue. Notably, 22 genes
were 5.4–148.4-fold up-regulated in dysplasia as compared to non-
transgenic lung tissue.
In particular Hnf4a (hepatocyte nuclear factor 4-alpha), Foxa3
(forkhead box gene A3) and Foxp2 (forkhead box gene P2) were
significantly over expressed in dysplasia (4.5–12.8-fold). These
genes codes for proteins that belong to a family of winged-helix/
forkhead DNA binding domain transcription factors and are
expressed in defined neural, intestinal, and cardiovascular cell
types during embryogenesis and differentiation of epithelium.
Hnf4a plays a key role in a transcriptional hierarchy and controls
the expression of other transcription factors such as Hnf1
(hepatocyte nuclear factor 1) [23]. Indeed, hundreds of genes are
targeted by Hnf4a. Since many of those genes contain more than
one Hnf4a binding site, these genes can be grouped into several
different categories, according to function, such as nutrient
transport and metabolism, blood maintenance, immune function,
cellular differentiation and growth factors. The best characterized
Hnf4a target genes are those involved in lipid transport (e.g.,
apolipoprotein genes) and glucose metabolism [24]. In this regard
Foxa genes code the winged helix/forkhead transcription factor
gene family that also includes Foxa1, Foxa2 and Foxa3, as well
[25]. Notably, Foxp2 is characterized as transcriptional repressor
and is the first Fox gene that is expressed exclusively in the distal
epithelium of the lung during pulmonary development [26].
Finally, we searched for expression of oncogenes and found the
proto-oncogene Ros1 (v-ros avian ur2 sarcoma virus oncogene
homolog 1), which encodes a transmembrane protein with a
sequence typical of tyrosine kinases to be 5.8-fold up-regulated in
dysplasia. Ectopic expression of this receptor tyrosine kinase Ros1
has been reported in many tumors of the central nervous system
and recently in lung and stomach cancers [27] as well. It has
been suggested that Ros1 plays a role in the mesenchymal
epithelial transition during development of kidney, lung and small
intestine [28].
Quantitative real-time PCR
To confirm the microarray data, expression of 8 genes in
dysplasia, transgenic and non-transgenic samples was examined by
quantitative real-time PCR using TaqMan Technology. qRT-
PCR confirmed that amphiregulin (Areg), epiregulin (Ereg), fetuin
beta (Fetub), apolipoprotein A1 (Apoa1), claudin 2 (Cldn2),
hepatic nuclear factor 4, alpha (Hnf4a), glutathione S-transferase,
alpha 4 (Gsta4) and forkhead box A3 (Foxa3) were up-regulated in
dysplasia (Supplementary Figure S2 and S3).
The expression data generated by the oligonucleotid array and
RT-PCR agreed well, therefore supporting the reliability of the
array analysis (Figure 7).
Immunohistochemistry
In order to validate array data as well as to add subcellular
localization, we performed immunohistochemical staining for
some differentially expressed genes. Immunohistochemistry using
antibodies towards amphiregulin, epiregulin, hepatocyte nuclear
factor 4 alpha, forkhead box A3 and forkhead box P2 showed a
consistent difference in immunoreactivity between dysplastic and
transgenic but otherwise unaltered cells (Figure 8). For all five up-
regulated proteins, patterns of immunoreactivity confirmed the
array data and quantitative real-time PCR results.
Discussion
This study aimed for a better understanding of the genetic
events associated with dysplasia in a genetic model of lung cancer
induced by overexpression of the c-Raf-1 kinase.
We aimed to determine the regulatory gene networks associated
with dysplasia. This enabled identification of candidate genes
specifically regulated at the edge of malignant transformation.
Based on hierarchical gene cluster analysis and principal-
component analysis we were able to distinguish the dysplastic
cells from transgenic and non-transgenic lung tissue.
To further validate the microarray data, we employed qRT-
PCR of selected genes, and confirmed by immunohistochemistry
regulated proteins in dysplastic foci.
Notably, RT-PCR data is suggestive for the microarray to
underestimate changes in the gene expression even though both
methods supported the general directions of changes. An
important finding of our study was that about 10% of the
differentially expressed genes regulated by $2 fold are already
known to be associated with lung cancer.
Specifically, in dysplasia genes coding for nucleic acid
metabolism or cell cycle regulation were unchanged but two
EGF-ligands, namely amphi- and epiregulin were highly signifi-
cantly up-regulated. These ligands enable autocrine loops to foster
undue EGF-signaling. Notably, Areg (amphiregulin) is a 252-
amino acid transmembrane glycoprotein and consist of two major
soluble forms of 78 and 84 amino acids, respectively. Areg was
originally isolated from conditioned medium of the human breast
carcinoma cell line MCF-7 and was found to be a heparin-binding
growth factor. Areg promotes neoplastic growth in mammary
epithelial cells, fibroblasts, and keratinocytes [29,30] and was
shown to function in an autocrine manner to drive the
proliferation of malignantly transformed cells of colon, breast,
cervix, prostate, and pancreas [31]. This ligand of the EGF
tyrosine kinase is commonly over expressed in cancers of human
colon, stomach, breast, and pancreas, in which the level of Areg
correlates with tumor progression and poor patient survival
Genetics of Dysplasia in Lung
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non-small cell lung cancer that the survival time of amphiregulin-
negative patients treated with gefitinib was significantly longer
than that of amphiregulin-positive patients. Therefore, an increase
in serum amphiregulin can be viewed as a predictor of resistance
to gefitinib [36]. Moreover, Areg was also reported as an inhibitor
of apoptosis in non-small cell lung cancer cell lines [37]. Our data
indicate that Areg secreted from dysplastic cells are in an autocrine
loop to foster malignant transformation.
A further growth factor strongly induced in dysplasia is Ereg
(epiregulin). The gene codes for a transmembrane precursor before
being proteolytically cleaved to release a 46-amino-acid activated
protein [38]. Ereg is promiscuous, binds and activates the Egfr
family member Erbb4 via heterodimeric interactions with Erbb2
[39]. Although Ereg expression is highly correlated with survival
from bladder cancer [40], others suggest epiregulin to be important
for pancreatic and prostate cancer development [41]. The strongest
evidence for a role of epiregulin during tumorigenesis was obtained
in Ki-ras-mediated signaling of colon cancer cells [42].
The fact that transformed cells grow faster than unaltered cells
is also sustained by our data with regard to the number and
strength of up-regulated genes affecting cellular growth. Specifi-
cally, the cell surface membrane proteins play an important role in
the behaviour of cells to allow for communication with other cells,
cell movement and migration, adherence to other cells or
structures and recognition by the immune system. Alterations of
the plasma membrane in malignant cells may thus be inferred
from a variety of properties that characterize their growth and
behaviour.
Our study is suggestive for changes in the glycosylation patterns
and in cell surface glycolipids. Changes in glycosylation can
include the presence of new carbohydrate structures that are not
detected in the normal epithelial cells and/or short carbohydrate
chains usually masked by larger epitopes. For example, we found
St8sia6 to be up-regulated in dysplasia. St8sia6 (alpha-2,8-
sialyltransferase VI) belongs to a family of sialyltransferases that
synthesize sialylglycoconjugates. The most frequently described
aberrant glycosylation in cancer cells include the synthesis of
highly branched and heavily sialyted glycans [43]. Because of the
negative electric charge of sialic acid at the terminal non-reducing
end of glycoprotein oligosaccharides, it plays a key role in
mediating biological recognition events, including those responsi-
ble for metastasis. Next, we found an overexpression of B4galt6
(UDP-GAL:Beta-GlcNAc Beta-1,4-Galactosyltransferase, poly-
peptide 6). This enzyme is involved in the production of GlcNAc
(galactose beta-1,4-N-acetylglucosamine). GlcNAc is the first sugar
residue to be linked to serine or threonine and serves as acceptor
for the elongation with further GlcNAc molecules. The resulting
branched structure may be elongated by the sequential addition of
galactose, fucose and sialic acid [44].
Changes of the glycosylation pattern in dysplasia enables further
variability in molecular assembly of membranes and offers a wide
range of flexibility in response to cellular environment. Their
detection on the cancer cell surface may provide useful diagnostic
or prognostic information but until now is incompletely under-
stood and therefore requires further elucidation.
Changes in the expression pattern of cell-adhesion molecules
and components of intercellular junctions are related to loss of
epithelial organization, proper cell layer and tissue polarity. With
regard to adhesion molecules, we found up-regulation of Chl1 (cell
adhesion molecule with homology to L1CAM), a member of the
L1 gene family of neural cell adhesion molecules, and of several
claudins as exemplified by the up-regulation of Cldn2 (claudin2),
Cldn4 (claudin4), and Cldn8 (claudin8), which are important
components of the tight junctions. Adhesion properties greatly
impacts cell-to-cell interaction and growth of cancer cells.
Figure 7. Comparison quantitative RT-PCR and Oligonucleotid-Array. Summary of differential expression of the eight genes verified by
quantitative RT-PCR in comparison with Oligonucleotid-Array analysis. The data were analyzed statistically using Student’s t-test (*p,0.05; **p,0.01).
Error bars indicate standard deviation of five samples and two independent assays for each gene.
doi:10.1371/journal.pone.0005637.g007
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106magnification, b) 406magnification) and in the presence of primary antibody preincubated with blocking peptide (c). 1=amphiregulin (AREG),
2=epiregulin (EREG), 3=hepatocyte nuclear factor 4 alpha (HNF4a), 4=forkhead box 3a (FOX3A/HNF3c), 5=forkhead box P2 (FOXP2). Strong,
mainly cytoplasmic immunoreactivity was found in dysplastic cells, whereas unaltered cells shown only weak positivity using the amphiregulin
antibody (1). Epiregulin immunostaining showed a cytoplasmatic pattern of immunoreactivity in dysplastic cells (2). The FOX3A antibody (3) showed
strong nuclear positivity in dysplastic cells, while unaltered transgenic cells were negative. The HNF4a antibody showed nuclear immunoreactivity (4).
Nuclear positivity was also restricted to dysplastic cells with no staining in unaltered transgenic cells using the FOXP2 antibody (5).
doi:10.1371/journal.pone.0005637.g008
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5637In this regard, the cytoskeleton, which represents a complex of
interconnected fibrillar elements, has been determined as an
important factor in mediating adhesion-independent and depen-
dent signalling. During morphogenesis, they determine cell shape
and polarity, and promote stable cell-cell and cell-matrix
adhesions through their interactions with cadherins and integrins,
respectively. Surprisingly, in dysplastic cells we did not identify
regulation of genes involved in the cytoskeleton.
Instead, we identified changes in cell to cell communication. In
our study Gjb3 (gap junction membrane channel protein beta 3)
and Gjb4 (gap junction membrane channel protein beta 4) were
significantly up-regulated. It was shown that the gap junctional
intercellular communication is a form of cell–to-cell signalling
thereby mediating the exchange of small molecules between
neighbouring cells [45]. The regulation of connexins and gap
junctions is a hallmark of carcinogenesis, while their induction in
cancer cells leads to reversal of the cancer phenotype, induction of
differentiation, and regulation of cell growth [46].
We also focused on genes coding for surfactant lipids in respiratory
epithelium.Surfactant is a complex mixture of lipids and proteins that
reduces surface tension at the air–liquid interface and prevents
alveolar collapse during respiration. Four surfactant proteins (SP)
with unique properties have been identified. SP-A and SP-D are
relatively hydrophilic proteins and contribute to innate defence of the
lung and surfactant homeostasis. SP-B and SP-C are hydrophobic
proteins that enhance surface-active properties of surfactant
phospholipid films [47]. In dysplastic epithelium we could not detect
regulated genes coding for surfactant proteins. However, nearly all of
the genes grouped under lipid metabolism that have been previously
linked to transport and secretion of lipid were regulated. For example,
Apoa1 (apolipoprotein A-I) is known to be the major protein moiety
of high-density lipoprotein (HDL) and is mainly produced in the liver
and the intestine but is also produced in vitro by some differentiated
cell lines established from human colorectal tumors [48].
We found Apoa1 (apolipoprotein A-1), Adcyap1 (adenylate
cyclase activating polypeptide 1), Ltb4dh (leukotriene B4 12-
hydroxydehydrogenase), Fst (follistatin), Inhbb (inhibin beta-B),
Clu (clusterin), Hnf4a (hepatic nuclear factor 4, alpha), Prokr1
(prokineticin receptor 1), Pla2g1b (phospholipase A2, group IB),
Sult2b1 (sulfotransferase family, cytosolic, 2B, member 1), St8sia6
(ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6),
Cyp1b1 (cytochrome P450, family 1, subfamily b, polypeptide 1)
and the Pthlh (parathyroid hormone-like peptide) to be regulated
with inferred roles in lipid metabolism.
For example, Adcyap1 (adenylate cyclase activating polypeptide
1) is a member of the secretin/glucagons/vasoactive intestinal
peptide (VIP) family of peptides. It has been localized by
immunohistochemistry to the central nervous system, digestive
tract and was shown to exhibit a variety of biological activities. It is
involved in synthesis of sulfatides, glycolipid, sphingolipid and
plays a role in the accumulation of estrogen and progesterone. It
was also reported that Adcyap1 can regulate the proliferation and
differentiation [49] and was shown to be overexpressed in
neuroblastoma [50] and breast cancer [51]. Likewise, Ltb4dh
(leukotriene B4 12-hydroxydehydrogenase) catalyzes the conver-
sation of leukotriene B(4) into 12-oxo-leukotriene B(4) and is
involved in reduction of 15-keto prostaglandin E1 and prosta-
glandin. It could be shown that Ltb4dh was overexpressed in Ta
urothelial cell carcinoma [52]. We also observed Pthlh (parathy-
roid hormone-like peptide) to be induced in dysplasia. This protein
is responsible for most cases of humoral hypercalcemia of
malignancy. Pthlh expression in tumor samples has also been
correlated with poor prognosis in breast cancer [53], renal
carcinoma [54] and colorectal tumors [55].
Because cellular growth and differentiation is depended on
highly co-ordinated transcriptional networks we also searched for
master regulatory proteins of respiratory epithelium. Notably,
morphogenesis and branching of respiratory epithelium depends
on the timely expression and activity of transcription factors.
Dynamic changes in transcriptional activation of lung-specific
genes are required to get an appropriate positioning of respiratory
epithelial cells with the mesenchyme-derived endothelial cells. If
this critical process is disturbed, this can lead to malignancy [56].
Transcription factors involved in differentiation of pulmonary
epithelium includes HNF3B (hepatocyte nuclear factor 3 beta also
termed Foxa2) [57], Ttf1 (transcription termination factor, RNA
polymerase I) [58], Foxf1 (forkhead box F1a) [59], Gata6 (GATA
binding protein 6) [60] and Gata5 (GATA binding protein 5) [61].
In our study some of these transcription factors were highly
significantly regulated in dysplasia i.e. Hnf4a, Foxa3 and Foxp2.
Notably, Hnf4a (hepatocyte nuclear factor 4 alpha), a member of
the steroid/thyroid hormone receptor superfamily is a transcrip-
tional activator [62] whose ligand has been identified as tightly
bound endogenous fatty acids [63]. We found Hnf4a to be highly
significantly induced (12.8-fold). Hnf4a regulates constitutive
expression of a large number of target genes encoding enzymes,
transporters and other nuclear receptors.
Among the genes regulated by HNF4a we found at least 11
target genes up-regulated in dysplasia i.e. Arg2 (arginase type 2),
Apoa1 (apoliporotein A1), Cyp1b1 (cytochrome P450, family 1,
subfamily B, polypeptide 1), Cldn2 (claudin 2), Fetub (fetuin beta),
Gpx2 (glutathione peroxidase 2), Gsta4 (glutathione S-transferase
A4), Gpc6 (glypican 6), Hpn (hepsin), Orm1 (orosomucoid 1) and
Lad1 (ladinin1) [64], therefore providing an important link
between induction of this transcription factor and up-regulation
of target genes.
Likewise, we found Foxa3 (forkhead box A3) to be induced 7.5-
fold. This protein belongs to a group of endoderm-related
developmental factors that are members of the forkhead box (Fox)
superfamily of transcription factors. They were first discovered by
their ability to bind to promotersof liver specific genes encoding a1-
antitrypsin and transthyretin [65]. Foxa genes are regulated in early
mouse embryo development [66] and are responsible, at least in
part, for metabolic regulation. Mice that lack Foxa3 display an
increase in the mRNA levels of various serum proteins and
glycolytic enzymes and show a low serum glucagon level [67].
We also found Foxp2 (forkhead box P2) to be up-regulated 4.5-
fold. This protein is a member of the new subfamily of winged-
helix/forkhead DNA binding domain transcription factor. It could
be shown that Foxp2 are expressed in the lung restricted to the
distal epithelium and may regulate lung epithelial-specific gene
transcription during embryonic development [68]. Foxp2 has been
characterized as a transcriptional repressor. All the known Fox
genes that were implicated in regulating lung expression were
characterized as transcriptional activators [26]. This finding
suggests that Foxp2 plays a role in the balance of transcriptional
activation and repression that is involved in regulating epithelial
cell identity and development of the lung. These processes are also
crucial for the transdifferentiation of alveolar type I to type II
epithelial cells, which are responsible for gas exchange and
surfactant protein expression essential for lung function.
Additionally, we have confirmed the up-regulation of Areg,
Ereg, Hnf4a, Foxa3 and Foxp2 by immunohistochemical staining.
The immunostaining showed a distinct pattern of immunoreac-
tivity in dysplastic cells with no staining in unaltered transgenic
cells. For example, immunohistochemical staining of Areg showed
a cytoplasmic immunoreactivity in dysplastic cells but not each cell
expressed this molecule equally strong.
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tional networks of the MAPK pathway and we did not observe
regulated genes coding for cell cycle or nucleotide metabolism.
Both processes are highly active in tumor cells but do not play a
big role in dysplastic cells prior to malignant transformation. In
this context we found two EGF ligands, Areg and Ereg to be
specifically up-regulated in dysplasia. While amphiregulin binds
exclusively to EGFR epiregulin binds to HER4 and mediates
aberrant activation of this receptor. Indeed, exaggerated EGF
tyrosine kinase activity is a probable cause for lung cancer. We
now evidence de novo expression of two ligands of EGFR in
dysplasia that are frequently over expressed in cancers. We did,
however, not observe increased transcript expression of the cancer
stem cell markers CD44, CD133 and the epithelial cell adhesion
molecule EpCAM. This may support the notion that dysplasia is a
facultative cancer where additional events need to occur that
enable malignant transformation. Taken collectively, the whole
genome expression data provided important information in the
multistage process of lung cancer. Our study revealed interesting
novel candidate genes and pathways that dissected the programme
of respiratory epithelium from transgenic into dysplasia and
eventually lung cancer. In the second part of our study we report
the additional genetic events that take place from dysplasia to
malignantly transformed cells and thus provide a molecular
rational for the multistage process in lung cancer.
Materials and Methods
SP-C/c-raf model
Animals were kept according to the Public Health Service
Policy on Humane Care and Use of Laboratory Animals and SP-
C/c-raf transgenic mice were obtained from the laboratory of
Prof. Ulf Rapp (University of Wu ¨rzburg, Germany), who bred the
mice in the C57BL/6/DBA/2 hybrid background. We kept the
SP-C/c-raf transgenic mice in the C57BL/6 background for at
least five generations.
Lung samples were derived from 5 SP-C/c-raf mice (aged 5–10
months); dysplastic and unaltered lung tissue were always isolated
from the same dysplasia-bearing transgenic mouse (aged 5–7
months). Endogenous normal lung tissue was studied of 5 non-
transgenic mice (aged 7–10 months). The non-transgenic litter-
mates (wild-type) served as control for transgenic effects.
Mice were sacrificed and the lung tissues were immediately
frozen on dry ice and stored at 280uC until further analysis.
The histopathological diagnosis was based on routinely
processed hematoxylin-eosin stains.
Microdissection (LMPC – Laser Microbeam
Microdissection and Laser Pressure Catapulting)
From each frozen lung tissue 10-mm thick sections were
prepared and transferred on polyethylene napthalate foil-covered
slides (Zeiss, P.A.L.M. Microlaser Technologies GmbH, Bernried,
Germany).
The sections were fixed in methanol/acetic acid and stained in
hematoxylin. The desired cells were microdissected using the
PALM MicroLaser systems (Zeiss, P.A.L.M. Microlaser Technol-
ogies GmbH, Bernried, Germany) and collected in an adhesive
cap (Zeiss, P.A.L.M. Microlaser Technologies GmbH, Bernried,
Germany). Microdissected cells were resuspended in a guanidine
isothiocyanate-containing buffer (RLT buffer from RNeasy
MikroKit, Qiagen, Santa Clarita, CA, USA) with 10 ml/ml b-
mercaptoethanol to ensure isolation of intact RNA. Approximate-
ly an area of 6610
6 mm
2 were pooled from a specific layer of
interest in the same animal and used for RNA extraction.
Following microdissection, total RNA-extraction was performed
with the RNeasy Micro Kit (RNeasy MicroKit Qiagen, Santa
Clarita, CA, USA) according to the manufacturer’s instruction. A
standard quality control of the total RNA was performed using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA).
cRNA labeling and hybridization to microarrays
Total RNA (median: 175 ng; range: 150–200 ng) was used to
generate biotin-labeled cRNA (10 mg) by means of Message Amp
aRNA Premium Amplification Kit (Ambion, Austin, TX). Quality
control of cRNA was performed using a bioanalyzer (Agilent 2001
Biosizing, Agilent Technologies). Following fragmentation, labeled
cRNA of each sample was hybridized to Affymetrix GeneChipH
Mouse Genome 430 2.0 Arrays covering over 34.000 genes and
stained according to the manufacturer’s instructions.
Quantification, normalization and statistical analysis
Array data was normalized using scaling or per-chip normal-
ization to adjust the total or average intensity of each array to be
approximately the same.
Microarray chips were analyzed by the GCOS (GeneChip
Operating Software) from Affymetrix with the default settings
except that the target signal was set to 500 and used to generate a
microarray quality control and data report. CEL files exported
from GCOS were uploaded into ArrayTrack software (National
Center for Toxicological Research, U.S. FDA, Jefferson, AR, USA
(NCTR/FDA)) and normalized using Total Intensity Normaliza-
tion after subtracting backgrounds for data management and
analysis. ArrayTrack software includes some tools common to
other bioinformatics software (e.g., ANOVA, T-test and SAM).
SAM
To compare the normalized data from dysplasia, normal lung
tissue from transgenic mouse, tumor cells and non-transgenic of
different mice, we used the Significance Analysis of Microarrays
(SAM) algorithm (ArrayTrack), which contains a sliding scale for
false discovery rate (FDR) of significantly up- and down-regulated
genes [69]. All data were permuted 100 cycles by using the two
classes, unpaired data mode of the algorithm. As cut-off for
significance an estimated FDR of 0.001 was chosen. Moreover, a
cut-off for fold-change of differential expression of 2 was used. The
full description of the extraction protocol, labeling and hybridiza-
tion protocol and data processing is obtainable in the GEO DATA
base under http://www.ncbi.nlm.nih.gov/geo/ [accession num-
ber GSE13963].
Principal component analysis (PCA) and hierarchical gene
cluster analysis (HCA)
Two clustering approaches were used to determine components
of variation in the data in this study as follows.
A) Principal-component analysis (PCA) that was used to obtain
a simplified visualization of entire datasets. PCA is a useful
linear approach to obtain a simplified visualization of entire
datasets, without losing experimental information (variance).
PCA allowed the dimension of complex data to be reduced
and highlights the most relevant features of a given dataset to
be highlighted.
B) Hierarchical gene clustering (HCA) where the data points
were organized in a phylogenetic tree in which the branch
lengths represent the degree of similarity between the values.
HCA were conducted using the ward’s minimum variance
linkage clustering algorithm within ArrayTrack. After
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genes were used for hierarchical clustering.
Functional analysis of the significant genes with IPA
Lists of significantly differentially expressed genes were
uploaded to Ingenuity Pathways Analysis (IPA, Ingenuity Systems
Inc., Redwood City, CA, USA) (www.Ingenuity.com) and
functional annotation and pathway analysis was performed. IPA
is a commercial, web-based interface that uses a variety of
computational algorithms to identify and establish cellular
networks that statistically fit the input gene list and expression
values from experiments. The analysis uses a database of gene
interactions culled from literature and updated every quarter of
the year.
Additionally, Venn diagrams were used to examine the overlap
of resulting lists of genes differentially expressed between the
different sample sets.
Quantitative real-time PCR
Corroboration of RNA expression data was performed by
realtime PCR using the ABI PRISM 7500 Sequence Detection
System Instrument (Applied Biosystems, Applera Deutschland
GmbH, Darmstadt, Germany). Total RNA (200 ng) underwent
reverse transcription using an Omniscript RT Kit (Qiagen, Santa
Clarita, CA, USA) according to the manufacturer’s instruction.
PCR reactions were performed according to the instructions of the
manufacturer using commercially available assays-on-demand
(Applied Biosystems, Applera Deutschland GmbH, Darmstadt,
Germany). CT values were calculated by the ABI PRISM software
and relative gene expression levels were expressed as the difference
in CT values of the target gene and the control gene Actin beta.
Immunohistochemistry
Each tumor section (8 mm in thickness) was deparaffinized in
roti-histol for 2 times 8 minutes, these were dehydrogenated by
means of a descending alcohol row. The following incubation steps
were accomplished: 2 times 3 minutes in 96% ethanol, 2 times
2 minutes in 70% Ethanol, and 2 minutes in Aqua dest. The pre-
treated slices were heated in a autoclave for 15 min in citrate
buffer submitted of an antigen retrieval before the colouring first.
For blocking endogenous peroxidase activity the slices covered for
30 minutes with 3% hydrogen peroxide/Methanol peroxidase
blocking solution. After a wash step, the slices were incubated with
the primary polyclonal anti-body against AREG, EREG, HNF4a,
FOXA3 and FOXP2 (Santa Cruz, Santa Cruz Biotechnologys
Inc., CA, USA) for 45 minutes. After washing, a streptavidin
horseradish peroxidase detection kit (Envision DAKO, Hamburg,
Germany) containing 3,39-diaminobenzidine solution as substrate
was used for immunohistochemical staining according to the
manufacturer’s instructions. Harris Ha ¨matoxylin was used as the
counterstaining.
The specificity of the immunostaining was confirmed by
negative control staining using mouse nonimmune immunoglob-
ulin G instead of the primary antibody.
Supporting Information
Table S1 List of genes with changed expressions that are
significantly overexpressed in dysplasia versus non-altered trans-
genic mice: 120 significantly regulated genes. This table shows the
RefSeq transcript IDs, Unigene IDs, gene titles, gene symbols, and
fold changes of the significantly regulated genes.
Found at: doi:10.1371/journal.pone.0005637.s001 (0.18 MB
DOC)
Table S2 List of genes with changed expressions that are
significantly over- or under-expressed in dysplasia versus non-
transgenic mice: 287 significantly regulated genes. This table
shows the RefSeq transcript IDs, Unigene IDs, gene titles, gene
symbols, and fold changes of the significantly regulated genes.
Found at: doi:10.1371/journal.pone.0005637.s002 (0.41 MB
DOC)
Table S3 List of genes with changed expressions that are
significantly over- or under-expressed in unaltered transgenic
versus non-transgenic mice: 18 significantly regulated genes. This
table shows the RefSeq transcript IDs, Unigene IDs, gene titles,
gene symbols, and fold changes of the significantly regulated
genes.
Found at: doi:10.1371/journal.pone.0005637.s003 (0.04 MB
DOC)
Figure S1 Ingenuity - Canonical Pathways. This figure shows
the canonical pathways which were overrepresented in the group
of significantly regulated genes in dysplasia versus transgenic mice.
Found at: doi:10.1371/journal.pone.0005637.s004 (2.13 MB
DOC)
Figure S2 Quantitative real-time PCR. Real-time PCR curves
of eight genes assessed by Taqman technology as well as of the
reference gene ACTB of a representative experiment are shown.
The differences of the Ct values of target and ACTB (deltaCT) are
indicated. The smaller the deltaCT, the higher the relative
expression level of the target mRNA.
Found at: doi:10.1371/journal.pone.0005637.s005 (6.75 MB
DOC)
Figure S3 Quantitative real-time PCR.
Found at: doi:10.1371/journal.pone.0005637.s006 (6.60 MB
DOC)
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